Advertisement
ISPR vs XXII
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISPR is a Hold and XXII is a Hold.
Momentum Indicator for ISPR turns negative, indicating new downward trend
ISPR saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 72 similar instances where the indicator turned negative. In 65 of the 72 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ISPR turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 34 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
ISPR moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ISPR broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISPR advanced for three days, in 133 of 161 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 45 of 49 cases where ISPR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.686) is normal, around the industry mean (-7.312). P/E Ratio (-2.345) is within average values for comparable stocks, (12.615). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.595). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. P/S Ratio (0.782) is also within normal values, averaging (2.780).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. ISPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock worse than average.
Momentum Indicator for XXII turns negative, indicating new downward trend
XXII saw its Momentum Indicator move below the 0 level on September 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 78 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XXII declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for XXII entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for XXII just turned positive on October 06, 2026. Looking at past instances where XXII's MACD turned positive, the stock continued to rise in 23 of 36 cases over the following month. The odds of a continued upward trend are 64%.
Following a +8.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where XXII advanced for three days, in 118 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
XXII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.008) is normal, around the industry mean (-7.312). P/E Ratio (0.000) is within average values for comparable stocks, (12.615). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.595). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. XXII's P/S Ratio (0.166) is slightly lower than the industry average of (2.780).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. XXII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XXII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock worse than average.
XXII | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 99 | |
P/E GROWTH RATING 1..100 | 96 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ISPR | XXII | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 69% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 64% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| Advances ODDS (%) | 15 days ago 83% | 22 days ago 69% |
| Declines ODDS (%) | 3 days ago 90% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 66% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ISPR’s FA Score shows that 2 FA rating(s) are green while XXII’s FA Score has 0 green FA rating(s).
- ISPR’s FA Score: 2 green, 3 red.
- XXII’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ISPR’s TA Score shows that 3 TA indicator(s) are bullish while XXII’s TA Score has 5 bullish TA indicator(s).
- ISPR’s TA Score: 3 bullish, 5 bearish.
- XXII’s TA Score: 5 bullish, 3 bearish.
Price Growth
ISPR (@Tobacco) experienced а +0.74% price change this week, while XXII (@Tobacco) price change was -65.61% for the same time period.
The average weekly price growth across all stocks in the @Tobacco industry was -5.55%. For the same industry, the average monthly price growth was -10.06%, and the average quarterly price growth was -19.94%.
Reported Earning Dates
ISPR is expected to report earnings on Nov 05, 2026.
XXII is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Tobacco (-5.55% weekly)The industry is engaged in the growth, preparation for sale, advertisement, and distribution of tobacco and tobacco-related products like cigarettes. In 2017, tobacco companies spent an estimated $9.36 billion marketing cigarettes and smokeless tobacco in the U.S. – an amount that translates to more than $25 million each day (according to a CDC report). Philip Morris International Inc., Altria Group Inc., and British American Tobacco plc are some major cigar makers. In recent times, vaping or the use of e-cigarette (does not burn tobacco) is gaining momentum – several established cigarette makers are trying to expand their footprint in this new market.
Advertisement
ISPR and
Correlation & Price change
A.I.dvisor tells us that ISPR and UVV have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISPR and UVV's prices will move in lockstep.
| Ticker / NAME | Correlation To ISPR | 1D Price Change % | ||
|---|---|---|---|---|
| ISPR | 100% | +2.26% | ||
| UVV - ISPR | 9% Poorly correlated | -0.96% | ||
| PM - ISPR | 3% Poorly correlated | -1.13% | ||
| RYM - ISPR | 0% Poorly correlated | +0.38% | ||
| XXII - ISPR | -1% Poorly correlated | -8.34% | ||
| AIIR - ISPR | -1% Poorly correlated | +2.84% | ||
More | ||||
XXII and
Correlation & Price change
A.I.dvisor tells us that XXII and RYM have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XXII and RYM's prices will move in lockstep.
| Ticker / NAME | Correlation To XXII | 1D Price Change % | ||
|---|---|---|---|---|
| XXII | 100% | -8.34% | ||
| RYM - XXII | 10% Poorly correlated | +0.38% | ||
| RLX - XXII | 7% Poorly correlated | -1.83% | ||
| BTI - XXII | 5% Poorly correlated | -1.64% | ||
| ISPR - XXII | 3% Poorly correlated | +2.26% | ||
| PM - XXII | 2% Poorly correlated | -1.13% | ||
More | ||||